Symmetry Partners’s United Therapeutics UTHR Stock Holding History

Symmetry Partners’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-3,566	Closed	-$1.14M	–	485
2024 Q2	$1.14M	Hold	3,566	–	–	0.06%	143
2024 Q1	$819K	Sell	3,566 -33	-0.9%	-$7.45K	0.06%	210
2023 Q4	$789K	Sell	3,599 -23	-0.6%	-$5.3K	0.04%	202
2023 Q3	$818K	Hold	3,622	–	–	0.04%	204
2023 Q2	$800K	Hold	3,622	–	–	0.04%	223
2023 Q1	$811K	Hold	3,622	–	–	0.04%	213
2022 Q4	$1.01M	Buy	3,622 +100	+3%	+$25.2K	0.06%	183
2022 Q3	$737K	Buy	3,522 +555	+19%	+$124K	0.05%	221
2022 Q2	$699K	Buy	2,967 +160	+6%	+$32.5K	0.05%	236
2022 Q1	$504K	Hold	2,807	–	–	0.03%	359
2021 Q4	$607K	Hold	2,807	–	–	0.04%	333
2021 Q3	$530K	Sell	2,807 -94	-3%	-$18.5K	0.03%	393
2021 Q2	$520K	Hold	2,901	–	–	0.03%	411
2021 Q1	$485K	Hold	2,901	–	–	0.03%	410
2020 Q4	$440K	Buy	2,901 +353	+14%	+$46.3K	0.03%	410
2020 Q3	$257K	Buy	2,548 +97	+4%	+$10.6K	0.02%	525
2020 Q2	$297K	Buy	+2,451	New	+$276K	0.04%	235

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Symmetry Partners's UTHR Position: Q3 2024 in Review

Symmetry Partners sold out of United Therapeutics (UTHR) in Q3 2024, closing a stake of 3,566 shares — an estimated $1.14M sold.

Symmetry Partners first reported a position in UTHR in Q2 2020 and held it in 17 quarters. The position peaked at $1.14M in Q2 2024. 625 funds tracked by Wall St. Rank hold UTHR as of Q3 2024.

Symmetry Partners reported no remaining United Therapeutics position as of Q3 2024 after selling out during the quarter.
Symmetry Partners sold 3,566 United Therapeutics shares in Q3 2024, an estimated $1.14M.
Symmetry Partners first reported a position in United Therapeutics in Q2 2020 and held it in 17 quarters.
Symmetry Partners's United Therapeutics position peaked at $1.14M in Q2 2024.
625 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2024.

Based on Symmetry Partners's 13F filing for Q3 2024, filed 29 Oct 2024.